Anadys Pharmaceuticals was founded in 1992 and is headquartered in San Diego, California. Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology. It develops ANA598, a small-molecule non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C; and ANA773, an oral toll-like receptor 7 agonist prodrug for the treatment of hepatitis C and cancer. The company was formerly known as Scriptgen Pharmaceuticals, Inc. and changed its name to Anadys Pharmaceuticals, Inc. in May 2000.

Javelin is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. Javelin’s product candidates address the acute moderate-to-severe pain medication market segment. We are developing differentiated pain control products that provide the flexibility and versatility required to address the limitations of existing prescription pain medications in supervised health care settings. Indications under development include post-operative pain, orthopedic injury pain, procedural pain, burn pain and trauma. Our product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. Javelin has three late stage product candidates in development: Dyloject™ (diclofenac sodium, injectable), Rylomine™ (intranasal morphine) and Ereska™ (intranasal ketamine).

Æterna Zentaris Inc. company was founded in 1991 and is headquartered in Quebec, Canada. Æterna Zentaris Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for endocrine therapy and oncology. Its lead product candidates in endocrinology are cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist that has completed Phase III trial for benign prostatic hyperplasia (BPH); and AEZS-130, an oral ghrelin antagonist in a Phase III trial as a diagnostic test for Growth Hormone Deficiency. Æterna Zentaris company's lead products in cancer are perifosine, a PI3K/Akt pathway inhibitor in Phase III for multiple myeloma, and AEZS-108, a Phase II clinical trial product for the treatment of advanced ovarian and endometrial cancers, as well as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma. Its pipeline also include compounds in pre clinical development, such as AEZS-115, an LHRH antagonist for endometriosis and urology; AEZS-120, an anti-cancer vaccine; AEZS-126 Erk and PI3K inhibitors for oncology; and AEZS-127 ErPC for oncology. Æterna Zentaris has partnership agreements with Shionogi and Co.; sanofi-aventis; Nippon Kayaku Co. Ltd.; Spectrum Pharmaceuticals, Inc.; Handok Pharmaceuticals Co., Ltd.; and Keryx Biopharmaceuticals, Inc.

Locus Pharmaceuticals' mission is discovering and developing drug treatments using a technology platform that integrates virtual drug design, medicinal chemistry, and biology. Through its Ansaris division the company researches small molecule treatments for a number of illnesses including HIV, cancer, and inflammatory conditions such as arthritis. The company aims to develop drug candidates in-house and partner with other drugmakers to co-develop drugs. Locus counts Novartis Institute of Biomedical Research and Ono Pharmaceuticals among its partners. The privately-held company is led by president Joan Lau. Investors include Norvartis Bioventures and founding investor, Prism Venture Partners.

CytRx Corporation company was founded in 1985 and is headquartered in Los Angeles, California. CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology.

LGC (Holdings) Limited company provides chemical, DNA and other scientific analysis through four operating divisions: LGC forensics, life and food sciences, research and technology, and LGC standards. Its customers are involved in such areas as drug development, health care services, chemicals and petrochemicals, law enforcement, and environmental quality and maintenance. The company's LGC Prochem unit sells enzymes, proteins, reagents, and other laboratory supplies. Investment firm 3i Group owns about 30% of LGC, as does its employees.

Norgine Limited was founded in 1906 and is based in Harefield, the United Kingdom with regional offices in Tunisia and Saudi Arabia. It has manufacturing sites in Dreux, France; and Hengoed, the United Kingdom. The company has subsidiaries in the United Kingdom, France, Germany, Belgium, the Netherlands, Denmark, Switzerland, Austria, Italy, and Spain, as well as in Australia, and South Africa. Norgine Limited is a subsidiary of Norgine Europe B.V. Norgine Limited, a specialty pharmaceutical company, develops, manufactures, and markets products in the areas of gastroenterology, hepatology, and pain management in Europe. It offers products for the treatment of chronic constipation and faecal impaction, bowel preparation prior to colonoscopy, ulcerative colitis, Crohn's disease, duodenal and benign gastric ulcers, traveler’s diarrhoea, and pain, as well as provides antitussive medications and products for the relief of smooth muscle spasm. The company also provides assistance in the development and launch of pharmaceutical products for companies.

Quick-Med Technologies, Inc. was founded in 1997 and is headquartered in Gainesville, Florida. Quick-Med Technologies, Inc., a life sciences company, develops technologies for the medical and consumer healthcare markets in the United States. Quick-Med Technologies's technologies under development include NIMBUS, a family of organic molecules or polymers that are bio-engineered to have antimicrobial, hemostatic, and other properties, which could be used in a range of medical device applications, including contact lenses, wound dressings, incontinence products, or disposable gloves; and Stay Fresh, a chemical formulation for textiles that provides a durable antimicrobial agent, which can be bonded to fibers or fabrics so as to retain the biocidal property through various launderings and is suitable for a range of applications, including apparel, sportswear, active wear, and work wear, as well as furnishings, such as linens, drapes, and towels. Its other technologies under development comprise NimbuDerm, a novel copolymer used as a persistent hand sanitizer; and MultiStat, a family of matrix metalloproteinase inhibitors that are used for the maintenance, healing, and repair of skin and eyes.

Beijing Tongrentang Co., Ltd. company makes and sells a variety of traditional Chinese herbal medicines under the Tongrentang brand. Products include treatments for a number of maladies including colds and fevers, and preparations designed to improve circulation and kidney function. Tongrentang also exports its herbal remedies and has expanded beyond Chinese borders through a number of joint ventures and subsidiaries, establishing retail drug stores and clinics specializing in traditional Chinese medicine. The company's origins date back more than 300 years as a family business offering its remedies in Beijing during the Qing Dynasty.

Genzyme and Medtronic are out to prove that it doesn't just take time to heal a broken heart. The two companies' joint venture, MG Biotherapeutics, was created in 2004 to develop new treatments for heart attacks and other cardiovascular conditions. The company in 2006 ceased enrollment of new patients in its Phase II clinical trial, which had been testing the use of cell therapy to repair damaged heart tissue following a heart attack, after evidence showed the trial would not be successful. MG Biotherapeutics is also engaged in long-term research into next-generation cell therapies and is developing a less-invasive, catheter-based delivery system for cell therapy using Medtronic's TransAccess technology.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.